RoslinCT

Executive Summary

RoslinCT is a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, with a particular focus on induced pluripotent stem cells (iPSCs) and CRISPR-edited products. Founded in 2006 and headquartered in Edinburgh, UK, the company leverages its heritage from the Roslin Institute to offer end-to-end services from process development to clinical and commercial manufacturing under cGMP standards. RoslinCT has been instrumental in manufacturing the first CRISPR-edited cell therapy, underscoring its technical expertise and strategic importance in the rapidly evolving cell and gene therapy landscape. As the industry matures and more therapies advance toward commercialization, RoslinCT is well-positioned to capture growing demand for specialized CDMO services, particularly in the iPSC and gene editing niches. The company operates in a high-growth segment where outsourcing of complex manufacturing is increasingly preferred by biotech firms lacking in-house capabilities. RoslinCT's early mover advantage in iPSC and CRISPR technologies, combined with its regulatory track record, provides a competitive moat. However, competition from larger CDMOs and technology-specific risks (e.g., scalability of iPSC differentiation) remain challenges. Overall, RoslinCT represents a compelling opportunity in the cell and gene therapy CDMO space, with potential for revenue acceleration as client pipelines advance. The company is private, limiting public financial disclosures, but its strategic partnerships and clinical-stage involvement suggest a strong growth trajectory.

Upcoming Catalysts (preview)

• Q4 2026Announcement of new GMP manufacturing facility expansion to increase capacity70% success
• Q2 2027Signing of a major long-term commercial manufacturing contract with a CRISPR therapy sponsor50% success
• Q3 2027FDA approval of a cell therapy manufactured by RoslinCT, validating its manufacturing platform40% success